ABSTRACT Platelet activating factor, a potent mediator ofinflammation, causes a sustained increase in airway responsiveness to methacholine in man and has been implicated in asthma. The effect ofthe beta2 agonist salbutamol (200 ug by inhalation) on platelet activating factor induced bronchoconstriction and airway hyperresponsiveness was studied in seven normal subjects in a double blind, crossover study. Salbutamol only partially inhibited the platelet activating factor induced fall in partial flow at 30% ofvital capacity (Vp3o) (mean percentage fall 47-6 (SEM 7'9); p < 0-001), whereas it completely blocked a similar degree of bronchoconstriction induced by methacholine. Salbutamol did not prevent the accompanying transient flushing and chest irritation and did not affect the transient neutropenia (mean % fall 69-5 (13.6); p < 0 01) or the rebound neutrophilia (mean % increase 84*7 (24 7); p < 0 05) that followed platelet activating factor. There was an increase in the airway responsiveness to methacholine following inhalation of platelet activating factor, the maximum mean change being a three fold increase in PC40 (the provocative concentration of methacholine causing a 40% fall in Vp3o) on day 3 (p < 0 01). Salbutamol caused a significant attenuation of this response on day 3 (p < 0-02) but had no significant effect on days 1 and 7. Thus a therapeutic dose of salbutamol caused partial inhibition of platelet activating factor induced bronchoconstriction and had a minimal effect on the increased bronchial responsiveness following platelet activating factor.
Introduction
Platelet activating factor is an inflammatory mediator that could contribute to several features of asthma. It is a potent bronchoconstrictor agent, and causes a sustained increase in bronchial responsiveness to methacholine,' a feature that is characteristic of asthmatic airways.2 It is chemotactic for the eosinophil,34 a prominent cell present in the airways of those with asthma, and it is extremely potent in inducing airway microvascular leakage.5
Beta adrenergic agonists are used as bronchodilator agents in asthma and are presumed to relax airway smooth muscle directly.6 Beta agonists are also potent inhibitors of histamine release from human lung mast cells,7 and in addition attenuate the in vitro release of mediators from activated neutrophils8 but not from eosinophils.9 At high concentrations they prevent the development of microvascular leakiness induced by inflammatory mediators in animals.'0 In view of the potential role of inflammatory mechanisms underlying the bronchial hyperresponsiveness of asthma," beta agonists may therefore be expected to have some beneficial effect. They have little effect, however, on the bronchial hyperresponsiveness that develops after allergen challenge. '2 To evaluate the effect of beta agonists further we have examined whether salbutamol, administered by aerosol at the therapeutic dose of 200 pg, inhibits the acute bronchoconstriction and bronchial hyperresponsiveness induced by platelet activating factor in normal subjects (in whom there is no question ofprior beta agonist treatment). We have also studied its effect on the transient but substantial leucopenia that occurs after inhalation of platelet activating factor. Methacholine challenge was performed with inhalation of increasing doubling concentrations of methacholine chloride (Sigma, UK).' The provocative concentration of methacholine needed to cause a 40% fall in baseline Vp30 (PCO) was computed from log concentration-response curves by linear interpolation.
MEASUREMENT OF CIRCULATING CELLS
Samples of venous blood (2 ml) were taken from an intravenous cannula inserted in a forearm vein before and five and 15 minutes after the first three inhalations of PAF for measurement of total white cell and platelet counts on a Coulter Counter 880 (Coulter Electronics, Hialeah, Florida). Differential cell counts were performed on 100 cells from blood smears stained with May-Grunwald-Giemsa by an independent observer unaware of the protocol. We also sampled blood in two subjects before and after inhalation of a bronchoconstrictor dose of methacholine.
DATA ANALYSIS
PC. values were log transformed before analysis. All data have been reported as means and standard errors.
To determine the effect ofPAF on airways responsiveness a two factor analysis of variance and the Newman-Keuls multiple range test were performed. '4 To determine whether salbutamol had an effect on PAF responses a paired t test was used to compare the values after salbutamol and placebo. P values less than 0 05 were considered significant.
Results
All subjects noticed facial flushing and coughing after inhaling the first dose of PAF; one subject described a raw feeling in the chest. Prior inhalation ofsalbutamol did not prevent these symptoms. The symptoms were considerably less after the second inhalation and were absent on subsequent inhalations. We have confirmed our previous observation that platelet activating factor causes immediate bronchoconstriction and a sustained increase in responsiveness to inhaled methacholine, with a maximal mean threefold decrease in mean PC., occurring three days after inhalation.'" Salbutamol at the usual therapeutic dose only partly inhibited the bronchoconstrictor response, whereas it completely inhibited a slightly greater bronchoconstrictor response to inhaled methacholine in the same subjects. It did not prevent the systemic and local symptoms caused by PAF inhalation nor did it affect the transient neutropenia. Salbutamol had only a small inhibitory effect on the increased bronchial responsiveness to PAF seen on day 3; it had no effect on the increased responsiveness seen on days 1 and 7 after inhalation of platelet activating factor. The mechanisms by which PAF induces a sustained increase in airways responsiveness remain speculative. This effect of platelet activating factor could be initiated through the induction of inflammation in the 300 X I si Platelet activating factor also has potent effects on airway microvascular permeability,5 and subsequent microvascular leakage leads to plasma extravasation and oedema of the airways. Because salbutamol, with its potent effects as an airway smooth muscle relaxant, only partially protected against the acute bronchial response to platelet activating factor, possibly the residual effect on Vp., is a reflection of oedema of the airways produced by PAF. In support of this possibility is the complete protection afforded by salbutamol against methacholine induced bronchoconstriction of the same degree as that caused by platelet activating factor in the same subjects. If part of the acute response to inhaled platelet activating factor were due to airway oedema, this might explain why there is no relation between the responsiveness to platelet activating factor and that to methacholine,' which is presumed to be only a smooth muscle constrictor. Furthermore, asthmatic subjects do not appear to be more sensitive to platelet activating factor than normal subjects.'8 This lack of hyperresponsiveness to a mediator in asthma was previously reported for leukotriene (LT) D4,'9 though subsequent studies showed that asthmatic subjects are hyperresponsive to LTC4 and LTD4.?'2' Increased airway wall thickness due to oedema has been proposed as a possible mechanism of increased bronchial responsiveness. 22 Whether airways oedema could persist for as long as three days or more after a single exposure to platelet activating factor is doubtful and the possibility that airways oedema is linked to airways hyperresponsiveness remains unproved.
It is worth comparing the effects of salbutamol on the airway effects produced by platelet activating factor and by antigen because PAF has been suggested as a putative mediator in asthma. Salbutamol comChung, Dent, Barnes pletely inhibits the early bronchoconstrictor response to antigen, but has no effect on the antigen induced bronchial hyperresponsiveness seen seven hours after challenge.'2 By contrast, salbutamol caused only partial inhibition of the bronchoconstriction induced by platelet activating factor and had a minimal effect in reducing PAF induced bronchial hyperresponsiveness on day 3 with no effect on the decrease in PC,40 on days 1 and 7. Overall, the effect of salbutamol on hyperresponsiveness was very small, and is in accordance with the lack of inhibition by beta adrenergic agonist drugs on allergen induced hyperresponsiveness. '2 This work was supported by the Asthma Research Council and the Medical Research Council.
